[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1189584A1 - Alpha amino acid composition and method for the treatment of skin - Google Patents

Alpha amino acid composition and method for the treatment of skin

Info

Publication number
EP1189584A1
EP1189584A1 EP99923126A EP99923126A EP1189584A1 EP 1189584 A1 EP1189584 A1 EP 1189584A1 EP 99923126 A EP99923126 A EP 99923126A EP 99923126 A EP99923126 A EP 99923126A EP 1189584 A1 EP1189584 A1 EP 1189584A1
Authority
EP
European Patent Office
Prior art keywords
acid
composition
group
alpha amino
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP99923126A
Other languages
German (de)
French (fr)
Other versions
EP1189584A4 (en
Inventor
Marvin E. Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EXCEL COSMECEUTICALS Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1189584A1 publication Critical patent/EP1189584A1/en
Publication of EP1189584A4 publication Critical patent/EP1189584A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin

Definitions

  • This invention relates generally to dermatological compositions and methods for their use. More specifically, the invention relates to dermatological compositions based upon alpha amino acids. Most specifically, this invention relates to dermatological compositions based upon alpha amino acids having a pH in the range of .5 to 5.
  • Retinoic acid, and other retinoid compounds are effective for treating acne, wrinkles and other skin conditions.
  • these materials can be very toxic and must be used under close medical supervision, and hence are prescription medications.
  • retinoids are expensive. Strongly corrosive materials such as phenol, mineral acids and halocarboxylic acids such as trichloroacetic acid have been used to treat damaged skin by peeling away the outer layers. These materials must also be used under medical supervision since they can produce serious damage if misapplied.
  • a number of formulations have been developed for dermatological preparations using alpha hydroxy acids and alpha keto acids. These acids are used at fairly high concentrations, in clinical settings, to produce superficial peeling of the skin.
  • compositions are also used at lower concentrations by consumers and paraprofessionals to smooth and condition the skin and reduce wrinkles. In many instances, these materials can still be irritating, and as a result compositions have been developed wherein buffering agents such as amphoteric compounds or alkaline materials have been added to the acids to raise their pH. Such compositions are shown in U.S. Patents 4,105,782; 4,105,783 and 5,091,171. In other instances, skin care compositions have been formulated utilizing ascorbic acid, and such compositions are shown in Patents 4,983,382 and 5,140,043.
  • compositions have been prepared utilizing relatively neutral species such as salts.
  • PCT Patent Application WO96/19182 discloses the use of inorganic salts, primarily of magnesium, manganese and various lanthanide elements for reducing skin irritation.
  • Patent 5,478,560 discloses the use of salts of mixed amines for treating dry skin.
  • the present invention provides a composition which has very good utility for treating skin conditions associated with dryness, aging, photodamage such as photopigmentation and keratoses as well as acne and seborrheic keratoses.
  • compositions for the treatment of skin are based upon alpha amino acids and has a pH in the range of .5 to 5.
  • Some of the preferred acids comprise alpha amino dicarboxylic acids, with aspartic and glutamic acid being some particularly preferred acids.
  • the compositions further include a strong acid which functions to solubilize the alpha amino acid, and the composition may further include a basic material for the purpose of adjusting the pH to the preferred range of .5 to 5.
  • the compositions of the present invention may also include ascorbic acid as well as inorganic salts, which most preferably comprise a mixture of salts obtained from the Dead Sea.
  • the present invention also concerns a method for formulating the therapeutic compositions, and in accord with the method, an alpha amino acid is dissolved in a solvent system which includes a strong acid, and this strong acid is neutralized so as to adjust the pH of the solution to the preferred range of .5 to 5. Also within the scope of the present invention is a method for treating skin which comprises applying the compositions of the present invention to the skin.
  • the present invention also is directed to a base for a dermatological composition which comprises ascorbic acid and a mixture of inorganic salts of alkali and/or alkaline metals in a carrier.
  • the base may further include urea.
  • compositions of the present invention improve the tone and texture of the skin and decrease wrinkling due to drying and aging.
  • the compositions also decrease photodamage to the skin such as photopigmentation and solar keratoses, and the compositions also operate to remove or decrease the severity of acne and seborrheic keratoses.
  • alpha amino acids are those acids in which the amine group is on the carbon which is alpha to the carboxylic acid moiety.
  • alpha amino acids have the formula set forth hereinbelow:
  • alpha amino acids are those amino acids having two carboxyl groups, and in which the amine group is alpha to at least one of the carboxyl groups.
  • alpha amino dicarboxylic acids Two of the particularly preferred alpha amino dicarboxylic acids which may be employed in the practice of the present invention are aspartic acid, shown at Formula 2 hereinbelow, and glutamic acid, shown at Formula 3 hereinbelow.
  • amino acids may be also present as salts or ions.
  • the materials of the present invention are of very low toxicity, and are relatively nonirritating to the skin; hence, they may be used in very high concentrations.
  • amino acid concentrations ranging up to 20%, by weight, are generally effective. In those situations where the composition is being employed in a clinical setting, and particularly when keratoses and other such conditions are being addressed, relatively high concentrations of the composition will be employed. In those instances where the material is being utilized in a nonclinical setting and/or relatively minor conditions are being treated, lower concentrations will suffice.
  • concentrations of amino acids in the range of .5-20% are employed, with concentrations in the range of 2-3% being sufficient for many treatment plans.
  • the amino acids of the present invention are disposed in a carrier, which in the simplest case comprises water.
  • a carrier in the simplest case comprises water.
  • water or alcohol based lotions as well as creams, ointments, gels and other such pharmaceutically acceptable carriers may be utilized.
  • carriers may further include fragrances, emollients, coloring agents, preservatives, and the like.
  • the alpha amino acids of the present invention are of relatively low solubility in water, weak acids or alcohol.
  • a solvent system which includes a strong acid therein.
  • strong acids are those acids which are highly ionized in solution and are generally categorized as having a dissociation constant (K A ) which is greater than 1.
  • Trichloroacetic acid is one strong acid which is preferably employed in the practice of the present invention.
  • the alpha amino acid is first dissolved in the solvent system which includes a strong acid therein.
  • a strong acid for example, it has been found that solutions of up to 20%, by weight, of trichloroacetic acid are highly effective solvents for aspartic acid, which is one of the particularly preferred alpha amino acids of the present invention.
  • solutions of up to 20%, by weight, of trichloroacetic acid are highly effective solvents for aspartic acid, which is one of the particularly preferred alpha amino acids of the present invention.
  • at least a portion of the remaining strong acid in the solution is neutralized so as to raise the pH of the solution to a therapeutically preferred range.
  • this range is from approximately .5 to approximately 5, and it has been found that the solubilized alpha amino acids remain in solution, in relatively high concentrations, at this pH range.
  • relatively low pHs of .5 to 2.0 may be effectively employed.
  • relatively higher pHs in the range of 2 to 3 are typically employed.
  • effective, stable compositions may be prepared having pHs as high as 5.
  • Neutralization of the acid may be carried out using any basic material which is compatible with the solvent system and physiologically acceptable.
  • One particularly preferred base comprises urea, and it is believed that the urea, or any resultant salt of urea, further enhances the therapeutic effect of the composition.
  • bases which may be advantageously employed are purines, as well as amines.
  • Ammonium hydroxide may also be effectively employed as a base, as may be inorganic bases such as sodium hydroxide and other alkali metal hydroxides.
  • the strong acid solubilization and neutralization steps may produce new chemical species which further enhance the efficacy of the alpha amino acids of the present invention.
  • Such enhancement may come from the formation of salts or from a chemical rearrangement of the amino acid, as for example by the addition of further carboxyl groups thereto, or by the formation of esters, imines, imides, amides and other such species.
  • the compositions of the present invention are based upon the use of therapeutic compositions of alpha amino acids, and more preferably alpha amino dicarboxylic acids.
  • the compositions are prepared by a method wherein strong acids are first employed to solubilize the alpha amino acids, and bases are then employed to adjust the pH of the resultant composition.
  • auxiliary ingredients may be added to the compositions.
  • ascorbic acid further enhances the efficacy of the compositions.
  • the ascorbic acid if employed, is present in an amount, by weight, of up to 5% of the composition, although higher concentrations such as 20% may be employed. While there is no lower limit to the amount of ascorbic acid which may be employed, typically, if it is employed at all, it is present in an amount of at least .5% by weight.
  • ascorbic acid comprises, by weight, .5-5% of the composition.
  • citric acid may be included in the compositions, in similar amounts.
  • compositions of the present invention may be formulated into a cream, gel or lotion base, using any pharmaceutically acceptable carrier.
  • the compositions may be formulated into a peel-off mask by employing a film forming carrier such as polyvinyl alcohol or an inorganic, mud pack type carrier such as a clay-based material.
  • a film forming carrier such as polyvinyl alcohol or an inorganic, mud pack type carrier such as a clay-based material.
  • colorings, fragrances, preservatives and the like may be similarly included in the compositions of the present invention.
  • Example 1 The following are some examples of compositions in accord with the present invention.
  • Example 1 The following are some examples of compositions in accord with the present invention.
  • a second composition was prepared utilizing a portion of the stock material prepared in Example 1.
  • 3%, by weight, of L-ascorbic acid was dissolved in the stock solution.
  • the thus produced clear solution did not crystallize out on standing, and the pH of the resultant solution was approximately
  • Example 4 A further composition was prepared from the stock solution of Example 1 by dissolving, by weight, 2% citric acid therein.
  • the resultant solution was storage stable, and had a pH of approximately 2.0, and manifested good therapeutic efficacy.
  • Example 4
  • Example 1 The stock solution of Example 1 was blended, on a 50% weight basis, with a conventional cold cream base to produce a cream composition.
  • the resultant cream was storage stable and had good therapeutic efficacy.
  • compositions can be prepared in accord with the present invention.
  • other alpha amino acids such as glutamic acid
  • Still other additives such as mineral salts
  • mineral salts may be employed in the compositions.
  • One particularly preferred group of mineral salts comprises minerals of the type found in the Dead Sea, or synthetic equivalents thereof. These minerals include mixtures of salts of Group I and Group II elements. Most specifically, such Dead Sea minerals comprise mixtures of carbonates, bicarbonates, halides and sulfates of potassium, magnesium, calcium and sodium. Salts, in an amount of up to 5% by weight of the composition, may be advantageously included therein.
  • the salts themselves may function as bases for the neutralization of excess acid.
  • auxiliary materials may be added to the compositions of the present invention.
  • other organic acids such as lactic acid, salicylic acid and the like may be included in the compositions.
  • Other therapeutic materials such as cortisones or topical anesthetics may be included in the compositions.
  • the amino acid compositions of the present invention may be disposed in a variety of pharmaceutically acceptable carriers such as lotions, gels and the like as described hereinabove.
  • a carrier base may be advantageously prepared from a mixture of ascorbic acid and mineral salts, most preferably Dead Sea mineral salts as described hereinabove.
  • the base may include urea. The base solubilizes and stabilizes the compositions of the present invention.
  • the base may be advantageously employed with the amino acid derived compositions of the present invention, it may also be employed with other dermatological compositions such as compositions based upon hydroxy acids, retinoids, inorganic materials and the like.
  • the base of the present invention further includes a vehicle, which in the simplest case may comprise water, or the vehicle may comprise lotion, cream, gel or ointment. It has been found that the ascorbic acid and salt interact to produce a smooth, oily composition which readily coats the skin and carries the remaining components of the composition. While not wishing to be bound by speculation, the inventor theorizes that the ascorbic acid and/or the salts interact with one another, and possibly chelate the amino acid or other carboxylic acid to stabilize it and moderate its effects.
  • Urea is one further ingredient which has been found beneficial in the base composition.
  • the urea may be derived from the amino acid based composition itself or may be added in addition.
  • the urea functions as a skin moisturizer and softener and facilitates penetration of various components of the composition into the skin.
  • the ascorbic acid is typically present in an amount of approximately 0.5 to 10%, and the mineral salts are typically present in amounts of between 1 and
  • urea is included in the composition, it is typically present in an amount of up to 5% and most preferably about 1%.
  • compositions for the treatment of the skin and methods for their fabrication, wherein the compositions include alpha amino carboxylic acids, and most preferably alpha amino dicarboxylic acids such as aspartic and glutamic acid.
  • the amino acids are preferably solubilized by the action of a strong acid, and the resultant composition neutralized to a therapeutically effective pH with a base such as urea or the like.
  • a base such as urea or the like.
  • a carrier base which includes ascorbic acid and mineral salts. The base may be used together with the amino acid compositions, or with prior art compositions such as hydroxy acids.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composition for the treatment of skin includes an alpha amino acid, which is most preferably an alpha amino dicarboxylic acid such as aspartic acid or glutamic acid. The composition has a pH in the range of .5 to 5. Also disclosed is a method for preparing the compositions wherein the amino acid is first solubilized in a strong acid, and the resultant solution then neutralized with a base to the therapeutic pH range. Also disclosed is a carrier for dermatological compositions comprising a solution of ascorbic acid and mineral salts.

Description

ALPHA AMINO ACID COMPOSITION AND METHOD FOR THE TREATMENT OF SKIN
Field of the Invention
This invention relates generally to dermatological compositions and methods for their use. More specifically, the invention relates to dermatological compositions based upon alpha amino acids. Most specifically, this invention relates to dermatological compositions based upon alpha amino acids having a pH in the range of .5 to 5.
Background of the Invention A large variety of materials and compositions have been employed for the topical treatment of skin conditions caused by drying, photodamage, aging, acne and the like. In addition to being effective and safe, any product used for the treatment of skin conditions should be convenient to formulate, easy to use, have long term stability, and be easy to handle. Additionally, such products should preferably be low in cost.
Retinoic acid, and other retinoid compounds are effective for treating acne, wrinkles and other skin conditions. However, these materials can be very toxic and must be used under close medical supervision, and hence are prescription medications. In addition, retinoids are expensive. Strongly corrosive materials such as phenol, mineral acids and halocarboxylic acids such as trichloroacetic acid have been used to treat damaged skin by peeling away the outer layers. These materials must also be used under medical supervision since they can produce serious damage if misapplied. A number of formulations have been developed for dermatological preparations using alpha hydroxy acids and alpha keto acids. These acids are used at fairly high concentrations, in clinical settings, to produce superficial peeling of the skin. They are also used at lower concentrations by consumers and paraprofessionals to smooth and condition the skin and reduce wrinkles. In many instances, these materials can still be irritating, and as a result compositions have been developed wherein buffering agents such as amphoteric compounds or alkaline materials have been added to the acids to raise their pH. Such compositions are shown in U.S. Patents 4,105,782; 4,105,783 and 5,091,171. In other instances, skin care compositions have been formulated utilizing ascorbic acid, and such compositions are shown in Patents 4,983,382 and 5,140,043.
In yet other instances, skin care compositions have been prepared utilizing relatively neutral species such as salts. PCT Patent Application WO96/19182 discloses the use of inorganic salts, primarily of magnesium, manganese and various lanthanide elements for reducing skin irritation. Patent 5,478,560 discloses the use of salts of mixed amines for treating dry skin.
As can be seen, there is a very large body of prior art directed to topical treatments for various dermatological conditions. The efficacy and safety of the various prior art compositions vary widely as do the cost and ease of formulating and using the compositions. Thus, there is still a need for a composition for treating dermatological conditions, which composition is effective, safe, easy to formulate and use and low in cost. As will be described hereinbelow, the present invention provides a composition which has very good utility for treating skin conditions associated with dryness, aging, photodamage such as photopigmentation and keratoses as well as acne and seborrheic keratoses. These and other advantages of the present invention will be apparent from the discussion and description which follow. Brief Description of the Invention
There is disclosed herein a composition for the treatment of skin. The composition is based upon alpha amino acids and has a pH in the range of .5 to 5. Some of the preferred acids comprise alpha amino dicarboxylic acids, with aspartic and glutamic acid being some particularly preferred acids. In particular embodiments of the invention, the compositions further include a strong acid which functions to solubilize the alpha amino acid, and the composition may further include a basic material for the purpose of adjusting the pH to the preferred range of .5 to 5. The compositions of the present invention may also include ascorbic acid as well as inorganic salts, which most preferably comprise a mixture of salts obtained from the Dead Sea.
The present invention also concerns a method for formulating the therapeutic compositions, and in accord with the method, an alpha amino acid is dissolved in a solvent system which includes a strong acid, and this strong acid is neutralized so as to adjust the pH of the solution to the preferred range of .5 to 5. Also within the scope of the present invention is a method for treating skin which comprises applying the compositions of the present invention to the skin. The present invention also is directed to a base for a dermatological composition which comprises ascorbic acid and a mixture of inorganic salts of alkali and/or alkaline metals in a carrier. The base may further include urea.
Detailed Description of the Invention In accord with one aspect of the present invention, it has been found that certain amino acids have a very beneficial therapeutic effect on the skin. The compositions of the present invention improve the tone and texture of the skin and decrease wrinkling due to drying and aging. The compositions also decrease photodamage to the skin such as photopigmentation and solar keratoses, and the compositions also operate to remove or decrease the severity of acne and seborrheic keratoses. Among the preferred amino acids are the alpha amino acids and within the context of this disclosure it is to be understood that alpha amino acids are those acids in which the amine group is on the carbon which is alpha to the carboxylic acid moiety. In general, alpha amino acids have the formula set forth hereinbelow:
Formula 1
R
O
-X
R
OH
R
Wherein the R groups are independently alkyl, aryl, heterocycles, or hydrogen. It is believed that the alpha configuration results in a beneficial chemical interaction between the amino acid and the skin. Among some of the most preferred alpha amino acids are the alpha amino dicarboxylic acids. As will be understood by those of skill in the chemical arts, alpha amino dicarboxylic acids are those amino acids having two carboxyl groups, and in which the amine group is alpha to at least one of the carboxyl groups. Two of the particularly preferred alpha amino dicarboxylic acids which may be employed in the practice of the present invention are aspartic acid, shown at Formula 2 hereinbelow, and glutamic acid, shown at Formula 3 hereinbelow. Formula 2
Formula 3
O . 0
CH CH "CH
HO OH
NH
It is to be understood that these amino acids may be also present as salts or ions. The materials of the present invention are of very low toxicity, and are relatively nonirritating to the skin; hence, they may be used in very high concentrations. However, it has been found that in most instances, amino acid concentrations ranging up to 20%, by weight, are generally effective. In those situations where the composition is being employed in a clinical setting, and particularly when keratoses and other such conditions are being addressed, relatively high concentrations of the composition will be employed. In those instances where the material is being utilized in a nonclinical setting and/or relatively minor conditions are being treated, lower concentrations will suffice. Typically, concentrations of amino acids in the range of .5-20% are employed, with concentrations in the range of 2-3% being sufficient for many treatment plans.
The amino acids of the present invention are disposed in a carrier, which in the simplest case comprises water. In other instances, water or alcohol based lotions as well as creams, ointments, gels and other such pharmaceutically acceptable carriers may be utilized. As is known in the art, carriers may further include fragrances, emollients, coloring agents, preservatives, and the like.
In some instances, the alpha amino acids of the present invention are of relatively low solubility in water, weak acids or alcohol. In addressing this problem, it has been found that further enhancements to the compositions of the present invention may be achieved if the alpha amino acid is first dissolved in a solvent system which includes a strong acid therein. As is known in the art, and within the context of this disclosure, strong acids are those acids which are highly ionized in solution and are generally categorized as having a dissociation constant (KA) which is greater than 1. Trichloroacetic acid is one strong acid which is preferably employed in the practice of the present invention. Other strong acids comprise other halocarboxylic acids such as fluoroacetic acids as well as mineral acids such as hydrochloric acid, sulfuric acid, perchloric acid and the like. In accord with this aspect of the present invention, the alpha amino acid is first dissolved in the solvent system which includes a strong acid therein. For example, it has been found that solutions of up to 20%, by weight, of trichloroacetic acid are highly effective solvents for aspartic acid, which is one of the particularly preferred alpha amino acids of the present invention. After the solution of the alpha amino acid is complete, at least a portion of the remaining strong acid in the solution is neutralized so as to raise the pH of the solution to a therapeutically preferred range. Typically, this range is from approximately .5 to approximately 5, and it has been found that the solubilized alpha amino acids remain in solution, in relatively high concentrations, at this pH range. In those instances where the composition of the present invention is being employed in a clinical setting, under professional supervision, relatively low pHs of .5 to 2.0 may be effectively employed. In those instances where compositions are being prepared for use in a home, or other nonprofessional setting, relatively higher pHs in the range of 2 to 3 are typically employed. In some instances, effective, stable compositions may be prepared having pHs as high as 5.
Neutralization of the acid may be carried out using any basic material which is compatible with the solvent system and physiologically acceptable. One particularly preferred base comprises urea, and it is believed that the urea, or any resultant salt of urea, further enhances the therapeutic effect of the composition.
Other bases which may be advantageously employed are purines, as well as amines. Ammonium hydroxide may also be effectively employed as a base, as may be inorganic bases such as sodium hydroxide and other alkali metal hydroxides.
While not wishing to be bound by conjecture, the inventor speculates that it is possible that the strong acid solubilization and neutralization steps may produce new chemical species which further enhance the efficacy of the alpha amino acids of the present invention. Such enhancement may come from the formation of salts or from a chemical rearrangement of the amino acid, as for example by the addition of further carboxyl groups thereto, or by the formation of esters, imines, imides, amides and other such species. In the broadest sense, the compositions of the present invention are based upon the use of therapeutic compositions of alpha amino acids, and more preferably alpha amino dicarboxylic acids. In yet more specific embodiments of the invention, the compositions are prepared by a method wherein strong acids are first employed to solubilize the alpha amino acids, and bases are then employed to adjust the pH of the resultant composition.
In accord with still other aspects of the present invention, yet other auxiliary ingredients may be added to the compositions. For example, it has been found that ascorbic acid further enhances the efficacy of the compositions. Most typically, the ascorbic acid, if employed, is present in an amount, by weight, of up to 5% of the composition, although higher concentrations such as 20% may be employed. While there is no lower limit to the amount of ascorbic acid which may be employed, typically, if it is employed at all, it is present in an amount of at least .5% by weight. In a most preferred embodiment of the invention, ascorbic acid comprises, by weight, .5-5% of the composition. In other instances, citric acid may be included in the compositions, in similar amounts. In yet other instances inorganic salts can be added to the composition, as will be elaborated upon hereinbelow. Yet other auxiliary ingredients may be employed in the compositions of the present invention. For example, the compositions may be formulated into a cream, gel or lotion base, using any pharmaceutically acceptable carrier. In some instances, the compositions may be formulated into a peel-off mask by employing a film forming carrier such as polyvinyl alcohol or an inorganic, mud pack type carrier such as a clay-based material. As is known in the art, colorings, fragrances, preservatives and the like may be similarly included in the compositions of the present invention.
The following are some examples of compositions in accord with the present invention. Example 1
5 grams of L-aspartic acid was dissolved in the solvent system comprising 100 grams of a 20% aqueous solution of trichloroacetic acid, at room temperature. This produced a clear and complete solution having a pH of less than 1. Solid urea was slowly added to the solution until the pH rose to approximately 3. It was found that this resultant solution was stable and did not crystallize out on standing.
The solution was found to have good therapeutic efficacy. Example 2
A second composition was prepared utilizing a portion of the stock material prepared in Example 1. In this example, 3%, by weight, of L-ascorbic acid was dissolved in the stock solution. The thus produced clear solution did not crystallize out on standing, and the pH of the resultant solution was approximately
3.0. The solution was stable on storage and had good therapeutic efficacy. Example 3
A further composition was prepared from the stock solution of Example 1 by dissolving, by weight, 2% citric acid therein. The resultant solution was storage stable, and had a pH of approximately 2.0, and manifested good therapeutic efficacy. Example 4
The stock solution of Example 1 was blended, on a 50% weight basis, with a conventional cold cream base to produce a cream composition. The resultant cream was storage stable and had good therapeutic efficacy.
Yet other compositions can be prepared in accord with the present invention. As discussed above, other alpha amino acids, such as glutamic acid, may be advantageously employed. Still other additives, such as mineral salts, may be employed in the compositions. One particularly preferred group of mineral salts comprises minerals of the type found in the Dead Sea, or synthetic equivalents thereof. These minerals include mixtures of salts of Group I and Group II elements. Most specifically, such Dead Sea minerals comprise mixtures of carbonates, bicarbonates, halides and sulfates of potassium, magnesium, calcium and sodium. Salts, in an amount of up to 5% by weight of the composition, may be advantageously included therein. In some instances, in which a strong acid is used to solubilize the amino acid, the salts themselves may function as bases for the neutralization of excess acid. Yet other auxiliary materials may be added to the compositions of the present invention. For example, other organic acids, such as lactic acid, salicylic acid and the like may be included in the compositions. Other therapeutic materials such as cortisones or topical anesthetics may be included in the compositions. The amino acid compositions of the present invention may be disposed in a variety of pharmaceutically acceptable carriers such as lotions, gels and the like as described hereinabove. In accord with yet another aspect of the present invention, it has been found that a carrier base may be advantageously prepared from a mixture of ascorbic acid and mineral salts, most preferably Dead Sea mineral salts as described hereinabove. In addition, the base may include urea. The base solubilizes and stabilizes the compositions of the present invention.
While the base may be advantageously employed with the amino acid derived compositions of the present invention, it may also be employed with other dermatological compositions such as compositions based upon hydroxy acids, retinoids, inorganic materials and the like. The base of the present invention further includes a vehicle, which in the simplest case may comprise water, or the vehicle may comprise lotion, cream, gel or ointment. It has been found that the ascorbic acid and salt interact to produce a smooth, oily composition which readily coats the skin and carries the remaining components of the composition. While not wishing to be bound by speculation, the inventor theorizes that the ascorbic acid and/or the salts interact with one another, and possibly chelate the amino acid or other carboxylic acid to stabilize it and moderate its effects. Urea is one further ingredient which has been found beneficial in the base composition. The urea may be derived from the amino acid based composition itself or may be added in addition. The urea functions as a skin moisturizer and softener and facilitates penetration of various components of the composition into the skin.
The ascorbic acid is typically present in an amount of approximately 0.5 to 10%, and the mineral salts are typically present in amounts of between 1 and
20%). In those instances where urea is included in the composition, it is typically present in an amount of up to 5% and most preferably about 1%.
It is thus to be appreciated that in accord with a first aspect of the present invention, there are provided therapeutic compositions for the treatment of the skin, and methods for their fabrication, wherein the compositions include alpha amino carboxylic acids, and most preferably alpha amino dicarboxylic acids such as aspartic and glutamic acid. The amino acids are preferably solubilized by the action of a strong acid, and the resultant composition neutralized to a therapeutically effective pH with a base such as urea or the like. Yet other ingredients may be further included in the compositions as detailed above. In accord with another aspect of the present invention, there is provided a carrier base which includes ascorbic acid and mineral salts. The base may be used together with the amino acid compositions, or with prior art compositions such as hydroxy acids.
Therefore, it is to be understood that in view of the teaching presented herein, numerous modifications and variations of the present invention may be implemented. The foregoing discussion and description are illustrative of some particular embodiments, but are not meant to be limitations upon the practice thereof. It is the following claims, including all equivalents, which define the scope of the invention.

Claims

Claims 1. A composition for the treatment of skin, said composition comprising: an alpha amino acid; and a pharmaceutically acceptable carrier, said composition having a pH in the range of .5-5.
2. A composition as in claim 1, wherein said alpha amino acid comprises an alpha amino dicarboxylic acid.
3. A composition as in claim 2, wherein said alpha amino dicarboxylic acid is selected from the group consisting of aspartic acid, glutamic acid, and combinations thereof.
4. A composition as in claim 1, further including a strong acid, in an amount sufficient to solubilize said alpha amino acid, and a base, in an amount sufficient to maintain said composition at said pH of .5-5.
5. A composition as in claim 4, wherein said strong acid is selected from the group consisting of a halocarboxylic acid, hydrochloric acid, perchloric acid and combinations thereof.
6. A composition as in claim 4, wherein said base is selected from the group consisting of urea, purines, amines, ammonium hydroxide, alkali metal hydroxides, and combinations thereof.
7. A composition as in claim 1, wherein the concentration of said alpha amino acid is, on a weight basis, in the range of .5-30%.
8. A composition as in claim 1, further including ascorbic acid.
9. A composition as in claim 8, wherein said ascorbic acid is present, on a weight basis, in the range of .5-5%.
10. A composition as in claim 1 , further including, on a weight basis, .5- 5% of an inorganic salt of an element selected from Group I or Group II of the periodic table.
11. The composition as in claim 10, wherein said elements from Group I or II of the periodic table are selected from the group consisting of potassium, magnesium, calcium, sodium, and combinations thereof; and wherein said salt is selected from the group consisting of carbonates, bicarbonates, halides, sulfates, and combinations thereof.
12. A composition as in claim 10, wherein said salts comprise a natural mixture of minerals obtained from the Dead Sea.
13. A composition for the treatment of skin consisting essentially of, on a weight basis: 0.5-20%) of a member selected from the group consisting of aspartic acid, glutamic acid, and combinations thereof; 0.5-20% of a strong acid selected from the group consisting of halocarboxylic acids, hydrochloric acid, sulfuric acid, and combinations thereof; a base, in an amount sufficient to adjust the pH of said composition to a value in the range of .5-5; 0-5%) of an inorganic salt of an element selected from Group I or Group II of the periodic table; 0-5%) ascorbic acid; and a pharmaceutically acceptable carrier.
14. A method for the preparation of a composition for the treatment of skin, said method comprising the steps of: providing an alpha amino acid; providing a solvent system for said alpha amino acid, said solvent system including a strong acid; dissolving said alpha amino acid in said solvent system so as to produce a solution thereof; and neutralizing at least a portion of the strong acid in said solution so as to adjust the pH thereof to a value in the range of .5-5.
15. A method as in claim 14, wherein the step of providing an alpha amino acid comprises providing an alpha amino dicarboxylic acid.
16. A method as in claim 15, wherein said alpha amino dicarboxylic acid is selected from the group consisting of aspartic acid, glutamic acid, and combinations thereof.
17. A method as in claim 14, wherein the step of providing a solvent system comprises providing a solvent system including a strong acid therein selected from the group consisting of halocarboxylic acids, hydrochloric acid, sulfuric acid, perchloric acid, and combinations thereof.
18. A method as in claim 14, wherein the step of neutralizing said solution comprising neutralizing said solution with a base selected from the group consisting of urea, purines, amines, ammonium hydroxide, alkali metal hydroxides, and combinations thereof.
19. A method as in claim 14, wherein the step of providing an alpha amino acid comprises providing, on a weight basis, .5-20% of said alpha amino acid.
20. A method as in claim 14, including the further step of disposing up to 5%, on a weight basis, of ascorbic acid in said solution.
21. A method as in claim 14, including the further step of disposing said solution in a pharmaceutically acceptable carrier.
22. A method for the treatment of skin comprising: applying a composition to said skin, said composition including an alpha amino acid, and having a pH in the range of .5-5.
23. A method for treating the skin as in claim 22, wherein said alpha amino acid comprises an alpha amino dicarboxylic acid.
24. A method as in claim 22, wherein said alpha amino acid is selected from the group consisting of aspartic acid, glutamic acid, and combinations thereof.
25. A method as in claim 22, wherein said composition further includes a strong acid and a base.
26. A method as in claim 25, wherein said strong acid is selected from the group consisting of a halocarboxylic acid, hydrochloric acid, perchloric acid, and combinations thereof.
27. A method as in claim 25, wherein said base is selected from the group consisting of urea, purines, amines, ammonium hydroxide, alkali metal hydroxides, and combinations thereof.
28. A method as in claim 22, wherein said composition further includes ascorbic acid therein.
29. A method as in claim 22, wherein said composition further includes an inorganic salt of at least one element selected from Groups I and II of the periodic table.
30. A method as in claim 29, wherein said element is selected from the group consisting of potassium, magnesium, calcium, sodium, and combinations thereof, and wherein said inorganic salt is selected from the group consisting of carbonates, bicarbonates, halides, sulfates and combinations thereof.
31. A base for a dermatological composition, said base comprising, on a weight basis; .5-10%) of a first carboxylic acid comprising ascorbic acid; 1 -5% of a salt mixture which includes at least two different inorganic salts, said salts including a cationic component selected from the group consisting of potassium, magnesium, sodium, and calcium; and an anionic component selected from the group consisting of carbonates, chlorides, fluorides, bromides, and sulfates; and a pharmaceutically acceptable carrier.
32. A composition as in claim 31 , further including, on a weight basis, .1-5% of urea.
33. A composition as in claim 31, further including a second carboxylic acid which is present, on a weight basis, in an amount of more than 0% and up to 60%, said second carboxylic acid being different from ascorbic acid, and being selected from the group consisting of alpha hydroxy acids, beta hydroxy acids, halogenated carboxylic acids, and salicylic acid.
34. A composition as in claim 31 , further including an alpha amino acid therein.
EP99923126A 1999-05-18 1999-05-18 Alpha amino acid composition and method for the treatment of skin Ceased EP1189584A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/010814 WO2000069403A1 (en) 1999-05-18 1999-05-18 Alpha amino acid composition and method for the treatment of skin

Publications (2)

Publication Number Publication Date
EP1189584A1 true EP1189584A1 (en) 2002-03-27
EP1189584A4 EP1189584A4 (en) 2006-01-25

Family

ID=22272771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99923126A Ceased EP1189584A4 (en) 1999-05-18 1999-05-18 Alpha amino acid composition and method for the treatment of skin

Country Status (3)

Country Link
EP (1) EP1189584A4 (en)
AU (1) AU3996799A (en)
WO (1) WO2000069403A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018114745A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions comprising poorly soluble compounds
CN110121330B (en) 2016-12-21 2022-04-29 联合利华知识产权控股有限公司 Personal care compositions with glutathione precursors comprising 4-substituted resorcinols and amino acids
JP2020502087A (en) 2016-12-21 2020-01-23 ユニリーバー・ナームローゼ・ベンノートシヤープ External skin lightening additive and composition containing amino acid and nicotinamide compound
EA201991185A1 (en) 2016-12-21 2020-01-13 Юнилевер Н.В. COMPOSITIONS FOR PERSONAL HYGIENE CONTAINING CYSTINE
IT201700104536A1 (en) * 2017-09-19 2019-03-19 Cmed Aesthetics Srl Topical products with two-phase system
AU2020267406A1 (en) * 2019-05-06 2021-12-16 Spinart, LLC Formulations and methods for preparing stable cosmetic compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0385155A2 (en) * 1989-02-21 1990-09-05 Klein, Peter, Prof.Dr.med. Cosmetic preparation for skin treatment
US5420106A (en) * 1994-03-22 1995-05-30 Bristol-Myers Squibb Company Method and composition having enhanced alpha-hydroxy acid skin permeation and retention
US5478560A (en) * 1990-10-19 1995-12-26 Shiseido Company Ltd. External dermatological composition
JPH09110634A (en) * 1995-10-16 1997-04-28 Ishiyoku Dougenshiya:Kk Skin protecting agent and its production

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2439013A1 (en) * 1978-10-19 1980-05-16 Serobiologiques Lab Sa COMPOSITION FOR USE IN PARTICULAR AS A COSMETIC PRODUCT FOR TANNING THE SKIN, INCLUDING THE USE OF AMINO ACIDS
JPS56125313A (en) * 1980-03-09 1981-10-01 Lion Corp Remedy for damage
US4707354A (en) * 1985-06-17 1987-11-17 Alpen Tau, Inc. Mature skin treatment and protectant compositions and methods of using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0385155A2 (en) * 1989-02-21 1990-09-05 Klein, Peter, Prof.Dr.med. Cosmetic preparation for skin treatment
US5478560A (en) * 1990-10-19 1995-12-26 Shiseido Company Ltd. External dermatological composition
US5420106A (en) * 1994-03-22 1995-05-30 Bristol-Myers Squibb Company Method and composition having enhanced alpha-hydroxy acid skin permeation and retention
JPH09110634A (en) * 1995-10-16 1997-04-28 Ishiyoku Dougenshiya:Kk Skin protecting agent and its production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 198146 Derwent Publications Ltd., London, GB; AN 1981-84292d XP002356453 & JP 56 125313 A (LION DENTIFRICE CO) 1 October 1981 (1981-10-01) *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 08, 29 August 1997 (1997-08-29) & JP 09 110634 A (ISHIYOKU DOUGENSHIA KK), 28 April 1997 (1997-04-28) *
See also references of WO0069403A1 *

Also Published As

Publication number Publication date
EP1189584A4 (en) 2006-01-25
AU3996799A (en) 2000-12-05
WO2000069403A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
US6197317B1 (en) Composition and method for the treatment of skin
US4234599A (en) Treatment of skin keratoses with α-hydroxy acids and related compounds
CA2257810C (en) Skin wash composition comprising an .alpha.-hydroxy acid or other acid and a detergent base
US4105782A (en) Treatment of acne and dandruff
JPH1072334A (en) Oxa-acid for care of skin state and related compound
US20050100519A1 (en) Topical L-carnitine compositions
EP0093186A1 (en) Pharmaceutical preparation for the topical treatment of acne
KR960000855A (en) L-carnitine salt and cosmetic composition and pharmaceutical composition for treating skin disease containing same
GB1589224A (en) Cosmetic compositions for the treatment of dry skin
EP0268911A2 (en) Solubilization of salts of pyridine-2-thiol-1-oxide
KR960010002A (en) L-carnitine salt and cosmetic composition and pharmaceutical composition for treating skin disease containing same
EP1189584A1 (en) Alpha amino acid composition and method for the treatment of skin
JP2002114670A (en) Antimicrobial skin care preparation
US6703030B2 (en) Amino fruit acid composition and method for the treatment of skin
US6436417B1 (en) Acne treatment compositions
EP1002525A3 (en) N-acylate derivatives of pyrrolidone carboxylic acid as surfactant
KR950000141A (en) Use of L-carnitine O-esters containing aromatic acids for the preparation of pharmaceutical compositions for the treatment of skin diseases
GB2210789A (en) Topical application for skin care
WO1997025050A1 (en) Compositions containing vitamin d derivatives for treatment of photodamaged skin
US7241808B2 (en) Composition for treatment of skin and method for stabilizing the composition
JPH07291823A (en) Improvement in or concerning cosmetic composition
JP3644809B2 (en) External preparation for head
JP2000507248A (en) Acne treatment
KR960010003A (en) L-carnitine salt and cosmetic composition and pharmaceutical composition for treating skin disease containing same
CA2049574A1 (en) Hair growth promoter

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20011207;LT PAYMENT 20011207;LV PAYMENT 20011207;MK PAYMENT 20011207;RO PAYMENT 20011207;SI PAYMENT 20011207

17P Request for examination filed

Effective date: 20011207

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EXCEL COSMECEUTICALS, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: EXCEL COSMECEUTICALS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20051212

17Q First examination report despatched

Effective date: 20070611

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110131